Krka UK Expands Tolracol Licence Across Pigs, Cattle and Sheep

Krka UK has expanded the licensed use of Tolracol® 50 mg/ml oral suspension, containing the anticoccidial active ingredient toltrazuril, strengthening the product’s positioning across the UK livestock sector.

The UK Veterinary Medicines Directorate’s current product database lists Tolracol 50 mg/ml Oral Suspension for cattle, pigs and sheep, with Krka as the marketing authorisation holder and the product classified as a POM-V veterinary prescription medicine.

Krka UK has specifically highlighted the extension allowing Tolracol to be used for prevention of clinical coccidiosis and reduction of oocyst shedding in suckler and bull beef calves, broadening its previous calf-health positioning.

Product and Disease Context

Toltrazuril is an anticoccidial compound used against coccidiosis caused by susceptible Eimeria species. In the calf application highlighted by Krka, the target organisms include Eimeria bovis and Eimeria zuernii.

Coccidiosis is particularly relevant in young livestock because intestinal damage can result in diarrhoea, reduced growth and poorer production performance. Importantly, disease can also occur subclinically, meaning production losses may occur without obvious clinical disease. Krka UK states that subclinical infection may affect a substantial proportion of calves on affected farms.

The broader Tolracol authorisation covers cattle, sheep and pigs, providing a multi-species product platform for livestock practices and producers managing different species. Regulatory databases also specify species-specific withdrawal requirements; for example, the EU veterinary medicines database lists meat-and-offal withdrawal periods of 63 days for cattle, 42 days for sheep and 77 days for pigs for the relevant authorisation.

Why the Extension Matters

The development is strategically relevant because coccidiosis management sits at the intersection of:

• Young-animal health

• Growth and feed efficiency

• Diarrhoea management

• Farm productivity

• Veterinary intervention

• Parasite-control programmes

• Antimicrobial stewardship

A broader livestock licence can also simplify product selection for veterinary practices and producers operating across multiple livestock categories.

However, the value of the extension is not simply the addition of another species indication. Effective coccidiosis control depends on farm-level epidemiology, timing of treatment, management, hygiene, stocking density and disease history.

Strategic / Analyst View

The livestock-health market is increasingly moving toward preventive intervention before measurable production losses occur.

For young ruminants and piglets, this creates an opportunity for animal-health companies to position anticoccidial products within broader young-animal health programmes, rather than as isolated treatments.

The strategic opportunity extends across diagnostics, parasite surveillance, nutritional support, gut-health products and farm-management interventions.

Outlook

Krka’s Tolracol extension strengthens the product’s multi-species positioning and illustrates the continuing commercial importance of targeted parasite control in young livestock.

For the animal-health industry, the broader opportunity is to integrate coccidiosis prevention with measurable outcomes such as growth performance, feed efficiency, diarrhoea reduction and reduced disease-treatment burden.

Regulatory note: The approved indication, dose, target species and withdrawal period must always be taken from the applicable local product label and veterinary authority. The UK authorisation should not be assumed to apply to India.